Other FXR agonists, such as ASC42 and WAY-362450, have been used to treat primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC) and liver fibrosis, and these diseases are the possible causes of hilar cholangiocarcinoma. This evidence concerns the gene NR1H4 and sclerosing cholangitis.